Nemaura Medical Appoints Samantha Sanders as Global Head of Digital Programs
April 15 2021 - 8:07AM
Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”),
a medical technology company focused on developing and
commercializing non-invasive wearable diagnostic devices and
supporting personalized lifestyle coaching programs, today
announced the appointment of Samantha Sanders as its Global Head of
Digital Programs.
Samantha has over two decades of project
development, management and customer service experience, delivering
successful digital projects to market within the wellbeing,
pharmaceutical and medical device sector, both locally and
internationally.
Prior to joining the Nemaura team, more recently
Samantha has been instrumental in the commercialization of bringing
medical and digital health products to market, working within the
regulations and requirements of both CE and FDA certification. She
has previously supported the design and led the project development
of digital applications for AbbVie Humira anti-TNF within the
Asian healthcare market. Samantha has established a wealth of
experience working across digital design, human-centered design and
preparation of product pre/post launch strategies.
“Samantha will lead the customer interface of
Nemaura’s digital portfolio, from a product design, product
placement, and customer service perspective. She takes a passionate
approach to ensure that products are designed with the user in
mind, developing and managing products that enhance everyday lives
and we are looking forward to her contribution to ensure optimized
access to our product portfolio for the end user,” commented Dr.
Faz Chowdhury, Nemaura’s Chief Executive Officer.
“Nemaura’s BEAT®diabetes program, and pipeline
consumer metabolic health product are both very exciting
alternatives to what’s currently available and I am delighted to
play a leading role in enhancing the digital presence of these
programs,” added Ms. Sanders.
About Nemaura Medical, Inc.
Nemaura Medical Inc. is a medical technology
company developing and commercializing non-invasive wearable
diagnostic devices. The company is currently commercializing
sugarBEAT® and proBEAT™. sugarBEAT®, a CE mark approved Class IIb
medical device, is a non-invasive and flexible continuous glucose
monitor (CGM) providing actionable insights derived from real time
glucose measurements and daily glucose trend data, which may help
people with diabetes and pre-diabetes to better manage, reverse,
and prevent the onset of diabetes. Nemaura has submitted a PMA
(Premarket Approval Application) for sugarBEAT® to the U.S. FDA.
proBEAT™ combines non-invasive glucose data processed using
artificial intelligence and a digital healthcare subscription
service and has been launched in the U.S. as a general wellness
product as part of its BEAT®diabetes program.
The Company sits at the intersection of the
global Type 2 diabetes market that is expected to reach nearly $59
billion by 2025, the $50+ billion pre-diabetic market, and the
wearable health-tech sector for weight loss and wellness
applications that is estimated to reach $60 billion by 2023.
For more information, please visit www.NemauraMedical.com.
Cautionary Statement Regarding Forward-Looking
Statements:
The statements in this press release that are
not historical facts may constitute forward-looking statements that
are based on current expectations and are subject to risks and
uncertainties that could cause actual future results to differ
materially from those expressed or implied by such statements.
Those risks and uncertainties include, but are not limited to, the
launch of proBEAT™ in the US, risks related to regulatory status
and the failure of future development and preliminary marketing
efforts, Nemaura’s ability to secure additional commercial
partnering arrangements, risks and uncertainties relating to
Nemaura and its partners’ ability to develop, market and sell
proBEAT™, the availability of substantial additional equity or debt
capital to support its research, development and product
commercialization activities, and the success of its research,
development, regulatory approval, marketing and distribution plans
and strategies, including those plans and strategies related to
both proBEAT™ digital health, and sugarBEAT®. There can be no
assurance that the company will be able to reach a part of or any
of the global market for CGM with its products/services. The FDA
reserves the right to re-evaluate their decision that proBEAT™
qualifies as a general wellness product should it become aware of
any issues such as skin irritation or other adverse events from the
device, as well as any misuse impacting patient safety, and any
other reason as the FDA may see fit at its discretion to determine
the product does not fit the definition of a general wellness
product. These and other risks and uncertainties are identified and
described in more detail in Nemaura’s filings with the United
States Securities and Exchange Commission, including, without
limitation, its Annual Report on Form 10-K for the most recently
completed fiscal year, its Quarterly Reports on Form 10-Q, and its
Current Reports on Form 8-K. Nemaura undertakes no obligation to
publicly update or revise any forward-looking statements.
Contact:
Jules Abraham CORE IR 917-885-7378 julesa@coreir.com
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Jun 2024 to Jul 2024
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Jul 2023 to Jul 2024